Chemotherapy for advanced gastric cancer (Q24236634)

2

0 references

author name string

Anna Dorothea Wagner

1

0 references

Wilfried Grothe

3

0 references

Gerhard Kleber

4

0 references

Axel Grothey

5

0 references

Wolfgang E. Fleig

Cochrane Database of Systematic Reviews

7

0 references

publication date

17 March 2010

0 references

published in

0 references

cites work

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

Phase II trial of UFT in advanced colorectal and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Sequential and combination chemotherapy of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Histologic types of gastric carcinoma in high- and low-risk areas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized study with mitomycin C + 5-fluorouracil+cytosine arabinoside (MFC)+5-fluorouracil, MFC+tegafur and uracil (UFT), and MF+UFT in advanced gastric cancer: interinstitutional differences in a multicenter study in Japan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

How should meta-regression analyses be undertaken and interpreted?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Docetaxel in combination for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Palliative Care: the World Health Organization's global perspective

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Gastric cancer epidemiology and risk factors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Thirty years of Medical Research Council randomized trials in solid tumours

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Cancer of the esophagogastric junction: epidemiology and pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Is there a role for second-line chemotherapy in advanced gastric cancer?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

One-year survey of carcinoma of the oesophagus and stomach in Wales

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Epidemiology of upper gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Extended lymph-node dissection for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Irinotecan in the treatment of gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

The decline in gastric cancer: epidemiology of an unplanned triumph

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Combination chemotherapy in advanced gastrointestinal malignancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer G

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Capecitabine in gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Doxorubicin and 5-fluorouracil versus doxorubicin and oral ftorafur in in the treatment of advanced gastric cancer--a phase II and III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB3

7 January 2021

10.1002/14651858.CD004064.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20238327

1 reference

Consolidated OpenCitations Corpus – April 2017